🔎 Trials Near Me

Akèy › Maladi Crohn › Kalifòni › Los Angeles

Etid klinik pou Maladi Crohn nan Los Angeles, CA

15 etid pou Maladi Crohn ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Ap rekriteFaz 3
  • Cedars Sinai Medical Center ( Site 5080), Los Angeles
  • UCLA Clinical & Translational Research Center (CTRC) ( Site 5116), Los Angeles
Laj 16 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT06430801

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Ap rekriteFaz 3
  • Cedars Sinai Medical Center, Los Angeles
Laj 2 a 17 · Tout sèks · Mizajou Sep 25, 2026 · NCT05923073

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Ap rekriteFaz 3
  • TLC Clinical Research Inc, Los Angeles
  • GastroIntestinal Bioscience, Los Angeles
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07499232

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Ap rekriteFaz 2/3
  • TLC Clinical Research Inc, Los Angeles
  • GastroIntestinal Bioscience, Los Angeles
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196722

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Ap rekriteFaz 3
  • TLC Clinical Research Inc.-Site Number: 8400030, Los Angeles
  • GastroIntestinal Bioscience - Los Angeles-Site Number: 8400019, Los Angeles
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

Ap rekriteFaz 2
  • Biopharma Informatic, LLC, Los Angeles
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07483099

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

Ap rekriteFaz 2
  • Biopharma Informatic, LLC, Los Angeles
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07483073

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Ap rekriteFaz 4
  • Cedars-Sinai Medical Center, Los Angeles
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06045754

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Ap rekriteFaz 3
  • Cedars Sinai Medical Center, Los Angeles
Laj 2 a 17 · Tout sèks · Mizajou Aug 24, 2026 · NCT05509777

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

Ap rekrite
  • Cedars-Sinai, Los Angeles
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT05230173

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Ap rekriteFaz 3
  • Keck Medicine Of USC - USC Healthcare Center 1, Los Angeles
Laj 18 a 65 · Tout sèks · Mizajou May 27, 2026 · NCT06227910

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

Ap rekriteFaz 4
  • Cedars-Sinai, Los Angeles
Laj 6 a 17 · Tout sèks · Mizajou May 27, 2026 · NCT05781152

Precise Infliximab Exposure and Pharmacodynamic Control

Ap rekriteFaz 2/3
  • Children's Hospital of Los Angeles, Los Angeles
Laj 6 a 22 · Tout sèks · Mizajou May 5, 2026 · NCT05660746

Impact of Prebiotics in Ulcerative Colitis

Ap rekrite
  • UCLA, Los Angeles
Laj 18 a 85 · Tout sèks · Mizajou Feb 27, 2026 · NCT06495658

Stem Cell Transplantation in Crohn's Disease

Ap rekriteFaz 1/2
  • Cedars-Sinai Medical Center, Los Angeles
Laj 13 a 28 · Tout sèks · Mizajou Feb 20, 2026 · NCT04224558

Etid Maladi Crohn nan lòt vil

Lòt etid nan Los Angeles

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.